Trial Profile
Venetoclax Plus Dose-adjusted R-EPOCH or R-CHOP for Richter's Syndrome
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Jan 2023
Price :
$35
*
At a glance
- Drugs Venetoclax (Primary) ; Colony stimulating factor modulators; Cyclophosphamide; Doxorubicin; Etoposide; Prednisone; Rituximab; Vincristine
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Richter's syndrome
- Focus Therapeutic Use
- 11 Jul 2022 Planned End Date changed from 1 Dec 2025 to 1 Dec 2027.
- 11 Jul 2022 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2024.
- 17 Nov 2021 Results (n=27) published in the Blood